Publications & Posters

Publications & Posters

JAMA Neurology | July 10, 2017
Conducted by the Mayo Clinic, the study looks at whether plasma total tau level can serve as a prognostic biomarker for cognitive decline and dementia and if those associations differ by elevated brain amyloid beta levels. Findings show that high levels of plasma total tau were associated with a…
PLOS ONE | July 5, 2017
We have developed a single probe method for detecting microRNA from human serum using single molecule arrays, with sequence specificity down to a single base, and without the use of amplification by polymerases.
Journal of Neurotrauma | June 30, 2017
There is an urgent need to characterize the acute physiological effects of sport-related concussion (SRC). We investigated the effects of SRC on gray matter structure and diffusion metrics in collegiate athletes at 1.64 days (T1; n=33), 8.33 days (T2; n=30), and 32.15 days (T3; n=36) post-…
Nucleic Acids Research | June 20, 2017
The high sensitivity and simple workflow of the Simoa method represent excellent advantages for miRNA-based diagnostics of human diseases.
Bioanalysis| June 19, 2017
Evaluation of three immunoassay-based technologies and their biomarker kits, by determining precision, parallelism and detectability of analytes of interest.
Multiple Sclerosis Journal| June 19, 2017
Neurofilament light chain (NFL) is a cerebrospinal fluid (CSF) marker of neuroaxonal damage in multiple sclerosis (MS).
Annual Reviews of Analytical Chemistry| June 12, 2017
Miniaturization of reaction volumes and confinement of analytes of interest into ultrasmall containers have greatly enhanced the sensitivity and throughput of many detection methods.
The Lancet Neurology | June 7, 2017
NfL in plasma shows promise as a potential prognostic blood biomarker of disease onset and progression in Huntington's disease.
Clinical Immunology | May 31, 2017
Delay in the diagnosis of multiple sclerosis (MS) stems from the lack of specific clinical and analytical markers to assist in the early diagnosis and prediction of progressive course.
Journal of Alzheimer's Disease| May 25, 2017
Plasma tau may serve as a non-specific marker for neurodegeneration but is still relevant to AD considering low GMD was associated with plasma tau in Aβ+ participants and not Aβ-participants.